FRCA Notes


Transcatheter Aortic Valve Implantation


  • The established treatment for severe aortic stenosis is surgical aortic valve replacement (SAVR)
  • TAVI may be preferable in an increasing number of patients, not just high-risk patients not suitable for SAVR but increasingly for those with lower risk surgical profiles too
  • TAVI now outnumbers SAVR in many developed countries
  • It overall benefits from avoiding sternotomy and cardiopulmonary bypass, thus improving recovery times from the procedure

  • The decision between TAVI and SAVR is made by the Heart Team, based on clinical, anatomical and procedural factors, lifetime management and life expectancy
  • The 2025 European guidelines recommend:
    • TAVI in patients ≥70yrs with tricuspid AS and suitable anatomy
    • SAVR in patients <70yrs with low surgical risk

  • For TAVI, such patients include:
    • Severe, symptomatic aortic stenosis in whom SAVR is not suitable and there will be an appreciable QoL benefit from the procedure
    • Where various patient characteristics favour TAVI over SAVR:
      • Advanced age
      • Significant comorbidity
      • Prior cardiac surgery, intact CABG or chest wall deformity
      • Porcelain aorta
      • Favourable vascular access
    • Putatively to facilitate other urgent non-cardiac surgery from which there is a survival benefit e.g. curative cancer surgery

Evidence base for TAVI (in brief)

  • All-cause 1yr mortality in high-risk surgical candidates similar to SAVR (PARTNER A Trial)
  • Reduced all-cause mortality & rehospitalisation vs. medical management alone, but higher risk of stroke (PARTNER B Trial)
  • Non-inferior all-cause 2yr mortality for intermediate-risk surgical candidates (PARTNER 2 & SURTAVI Trials)
  • Little-to-no difference for all-cause mortality, stroke, MI or cardiac death in low-risk surgical candidates (PARTNER 3, Cochrane)

Non-aortic stenosis indications for TAVI

  • Bicuspid aortic valve stenosis
  • Degenerated surgical bioprosthetic valve (i.e. instead of re-do cardiac surgery)
  • Aortic regurgitation (off-label use of procedure)

  • Active endocarditis (absolute)

  • Significant medical comorbidity with life expectancy <2yrs, e.g.:
    • Significant frailty
    • End-stage renal or respiratory disease
    • Severe mitral regurgitation
    • Severe pulmonary hypertension

  • Inadequate annulus size (either <1.8cm or >3cm)
  • Difficult anatomy
  • Mixed aortic valve disease or using TAVI for AR
  • Mobile thrombi in ascending aorta
  • Recent MI (1 month) or CVA (6 months)

Planning

  • Performed in a specialist centre with cardiac and vascular surgical support available
  • Large 'heart' MDT consisting of cardiology, cardiothoracics, vascular, radiology and anaesthetic consultants

  • Decision-making should not be guided by cardiac surgical risk scoring systems alone, but incorporate information regarding:
    • Clinical profile
    • Co-existing comorbidities
    • Functional status and frailty
    • Anatomical/technical factors inc. anticipated complexity
    • Pre-operative imaging e.g. gated cardiac CT

  • Adequate availability of cardiothoracic surgeons and perfusionists is required in case open approach and CPB is required mid-procedure

Vascular access

  • Primary access for the delivery sheath
    • Modern sheaths are 12-14Fr, reducing vascular trauma and improving tolerance compared to older sheaths
    • The most common route is trans-femoral (90%)
    • Other routes include:
      • Trans-subclavian: shorter valve delivery distance means more accurate positioning and may reduce some complications
      • Trans-apical; most invasive with a number of complications, but useful if trans-aortic approaches are unavailable
      • Trans-aortic; requires mini-sternotomy but may be necessary if other routes unavailable
      • Trans-carotid is described

  • Secondary access for 6Fr sheath, often right radial artery

Anticoagulation

  • Heparin IV bolus, titrated to ACT (target ~250s)
  • Full-dose protamine reversal at the end
  • Bivalirudin is reserved for those with heparin allergy or HIT

Valve deployment

  • Options include:
    • Direct implantation of new valve, especially if there has been antecedent balloon valvuloplasty
    • Dilation of AV by balloon valvuloplasty then deployment of the new valve

  • Balloon valvuloplasty and balloon-expandable valves require temporary, rapid ventricular pacing in order to prevent migration of the balloon/valve
    • Pacing may be delivered via a venous pacing wire (femoral vein or RIJV) or directly via the LV guidewire, avoiding the need for a separate venous wire
    • Rate 180-220bpm
    • Associated intentional reduction in systolic arterial pressure to ≤50mmHg for 5-10s
  • Self-expanding valves may not need rapid pacing, which further improves tolerance of the procedure

Post-insertion

  • Device position and function is assessed using TTE or TOE
  • Vasculature is assessed with angiography
  • Vessels and entry points are repaired in standard fashion
  • ECG checked for dysrhythmia
    • Patients with a normal PR and QRS interval after TAVI tend not to develop delayed high-degree conduction disorders so the TPW is often removed
    • Otherwise patients may need ongoing temporary or even permanent pacing

Perioperative Management of the Patient Undergoing TAVI


  • Planning as above (see: Surgical Process section)
  • Pre-operative assessment of the patient with aortic stenosis

Anaesthetic planning

  • Assess suitability for an awake technique:
    • Ability to lie flat and still for the procedure
    • Cognition and ability to co-operate
    • Anxiety
    • Airway assessment in case of conversion to GA
    • Local anaesthetic allergy
  • Shared decision-making regarding being awake vs. asleep, including the benefits (faster recovery vs. avoiding procedural discomfort) and risks of each
  • Identify high-risk features which may warrant additional invasive monitoring

Optimisation

  • Frailty assessment
  • Haemoglobin optimisation, e.g. iron ± erythropoiesis-stimulating agents (darbepoetin alfa)

  • Suffers from risks of remote anaesthesia as usually performed in cardiac catheter lab
  • An anaesthetist should be present or immediately available throughout, as complications may require rapid conversion to GA and resuscitation

Monitoring and access

  • AAGBI
  • Continuous invasive arterial monitoring is provided by the interventional access sites
  • Large bore IV access in case of haemorrhagic complications
  • Percutaneous defibrillation pads
  • TTE - TOE is not needed routinely but may be useful in complex cases or emergencies

  • Additional invasive monitoring is reserved for selected high-risk patients:
    • Additional arterial line ± CVC: haemodynamic instability, untreated CAD or RV dysfunction, particularly with an LVEF <30%
    • Additional arterial line: high-risk patients with renal failure (CKD stage ≥3), severe COPD or liver cirrhosis
    • Urinary catheter: only in those with severely reduced LVEF and advanced CKD

Not recommended

  • Pulmonary artery catheter
  • Pulse contour cardiac output monitoring
  • Routine BIS in low-risk patients (unless TIVA)
  • Routine urinary catheterisation

Anaesthetic technique

  • A spectrum of options exists for trans-femoral TAVI:
    • LA alone ('minimalist approach')
    • LA + conscious sedation (the most common technique)
    • Deep sedation
    • GA

  • Two large RCTs (SOLVE-TAVI and DOUBLE-CHOICE) have shown no difference in outcome between techniques
  • In both trials, conversion to a deeper technique was associated with higher mortality
  • This does not prove causation but signals that an unplanned change in anaesthetic plan is a marker of risk
Advantages of LA ± sedation Disadvantages of LA ± sedation
↓ need for vasoactive drugs Patient discomfort, anxiety and stress, particularly with LA alone
Negates need for invasive ventilation Patient movement may affect valve positioning
Facilitates intra-procedure neurological monitoring Unprotected airway
Shorter procedural time Conversion may be required in an emergency, in the catheter lab, in a supine patient with AS
↓ need for ICU Intra-procedural TOE not possible
Shorter length of stay
More economical

  • GA may still be required and is as per perioperative management of aortic stenosis
    • Benefits from immobile patient and ability to perform intra-procedure TOE
    • Consider for those unable to lie still or co-operate, or for patient preference

  • Cardiology ward or CCU in most uncomplicated cases
  • If I&V, extubate on CICU following standard post-cardiac surgery protocols

  • Maintain a high-normal intravascular volume status as:
    • There is poor LV compliance and diastolic dysfunction, so generally need higher filling pressures
    • There may be dynamic LVOT obstruction owing to a small LV cavity but normal contractility
  • VTE prophylaxis as indicated
  • DAPT for 1yr, then single agent therapy lifelong

  • Often minimal analgesic requirements for trans-femoral approach
  • Other approaches may have greater analgesic requirements e.g.:
    • Trans-apical: consider paravertebral or serratus anterior plane blocks + PCA
    • Trans-carotid: consider superficial cervical plexus block ± PCA

  • Early mobilisation and physiotherapy
  • Fast-track pathways allow next-day discharge in selected patients; otherwise generally discharged 48-72hrs post-operatively

  • 30-day mortality is now ~1-2%, but major or life-threatening complications occur in up to 10%
  • Females may be at higher risk of a number of in-hospital complications and all-cause mortality

Vascular

  • Overall rate of vascular complications 3-4%
    • Puncture site haemorrhage inc. retroperitoneal haemorrhage
    • Femoral artery pseudoaneurysm
    • Dissection
    • Vascular rupture
    • Bowel ischaemia due to atheromatous emboli

Conduction abnormalities

  • May be due to direct damage to the AVN or bundle of His

  • LBBB (most common)
  • LV asystole or PEA during the procedure
  • Complete heart block
  • ~5% need PPM post-procedure

Peri-valvular

  • Paravalvular leak ± aortic regurgitation
  • Annulus rupture (<1%); naturally associated with a poor prognosis
  • Para-aortic haematoma
  • Aortic root rupture
  • Late valve failure (rare)

Coronary artery occlusion

  • Typically due to displacement of the native calcified valve leaflet over the coronary ostium
  • May warrant catheterisation of the coronary arteries prior to implanting the valve to ensure easy access to re-open occluded arteries
  • Patients who are undergoing valve-in-valve (i.e. redo) TAVI are at higher risk
  • Overall incidence <1% but associated with poor outcome

Anaesthetic

  • Unplanned conversion from LA to sedation, or sedation to GA - associated with higher mortality
  • Airway obstruction or hypoventilation with unintentionally deep sedation

Other

  • Conversion to open surgery
  • Stroke (2-5%)
  • Delirium (higher risk if GA technique used; 53% vs. 12% for sedation)
  • Acute rise in creatinine (5-28%)